Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 3
2005 7
2007 3
2009 2
2010 1
2011 3
2012 1
2013 4
2014 7
2015 9
2016 17
2017 9
2018 9
2019 4
2020 4
2021 1
2022 2
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, Mansukhani S, Davies MN, Furness A, Sclafani F, Peckitt C, Jiménez M, Kouvelakis K, Ranftl R, Begum R, Rana I, Thomas J, Bryant A, Quezada S, Wotherspoon A, Khan N, Fotiadis N, Marafioti T, Powles T, Lise S, Calvo F, Guettler S, von Loga K, Rao S, Watkins D, Starling N, Chau I, Sadanandam A, Cunningham D, Gerlinger M. Woolston A, et al. Among authors: peckitt c. Cancer Cell. 2019 Jul 8;36(1):35-50.e9. doi: 10.1016/j.ccell.2019.05.013. Cancer Cell. 2019. PMID: 31287991 Free PMC article.
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Rugge M, Valeri N, Okines A, Hewish M, Allum W, Stenning S, Nankivell M, Langley R, Cunningham D. Smyth EC, et al. Among authors: peckitt c. JAMA Oncol. 2017 Sep 1;3(9):1197-1203. doi: 10.1001/jamaoncol.2016.6762. JAMA Oncol. 2017. PMID: 28241187 Free PMC article.
Response.
Sclafani F, Cunningham D, Peckitt C, Watkins D. Sclafani F, et al. Among authors: peckitt c. J Natl Cancer Inst. 2016 Jan 11;108(3):djv405. doi: 10.1093/jnci/djv405. Print 2016 Mar. J Natl Cancer Inst. 2016. PMID: 26754850 No abstract available.
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
Smyth EC, Vlachogiannis G, Hedayat S, Harbery A, Hulkki-Wilson S, Salati M, Kouvelakis K, Fernandez-Mateos J, Cresswell GD, Fontana E, Seidlitz T, Peckitt C, Hahne JC, Lampis A, Begum R, Watkins D, Rao S, Starling N, Waddell T, Okines A, Crosby T, Mansoor W, Wadsley J, Middleton G, Fassan M, Wotherspoon A, Braconi C, Chau I, Vivanco I, Sottoriva A, Stange DE, Cunningham D, Valeri N. Smyth EC, et al. Among authors: peckitt c. Gut. 2021 Sep;70(9):1632-1641. doi: 10.1136/gutjnl-2020-322658. Epub 2020 Nov 16. Gut. 2021. PMID: 33199443 Free PMC article. Clinical Trial.
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.
Rao S, Sclafani F, Eng C, Adams RA, Guren MG, Sebag-Montefiore D, Benson A, Bryant A, Peckitt C, Segelov E, Roy A, Seymour MT, Welch J, Saunders MP, Muirhead R, O'Dwyer P, Bridgewater J, Bhide S, Glynne-Jones R, Arnold D, Cunningham D. Rao S, et al. Among authors: peckitt c. J Clin Oncol. 2020 Aug 1;38(22):2510-2518. doi: 10.1200/JCO.19.03266. Epub 2020 Jun 12. J Clin Oncol. 2020. PMID: 32530769 Free PMC article. Clinical Trial.
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.
Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M. Bogaerts J, et al. Among authors: peckitt c. Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24. Eur J Cancer. 2015. PMID: 25542058 Free PMC article. Review.
Visualising harms in publications of randomised controlled trials: consensus and recommendations.
Phillips R, Cro S, Wheeler G, Bond S, Morris TP, Creanor S, Hewitt C, Love S, Lopes A, Schlackow I, Gamble C, MacLennan G, Habron C, Gordon AC, Vergis N, Li T, Qureshi R, Everett CC, Holmes J, Kirkham A, Peckitt C, Pirrie S, Ahmed N, Collett L, Cornelius V. Phillips R, et al. Among authors: peckitt c. BMJ. 2022 May 16;377:e068983. doi: 10.1136/bmj-2021-068983. BMJ. 2022. PMID: 35577357 Free PMC article.
Does cancer research focus on areas of importance to patients?
Moorcraft SY, Sangha A, Peckitt C, Sanchez R, Lee M, Pattison N, Wiseman T. Moorcraft SY, et al. Among authors: peckitt c. Ecancermedicalscience. 2016 Jan 7;10:ed51. doi: 10.3332/ecancer.2016.ed51. eCollection 2016. Ecancermedicalscience. 2016. PMID: 26823685 Free PMC article.
Genomic loss of heterozygosity and survival in the REAL3 trial.
Smyth EC, Cafferkey C, Loehr A, Waddell T, Begum R, Peckitt C, Harding TC, Nguyen M, Okines AF, Raponi M, Rao S, Watkins D, Starling N, Middleton GW, Wadsley J, Mansoor W, Crosby T, Wotherspoon A, Chau I, Cunningham D. Smyth EC, et al. Among authors: peckitt c. Oncotarget. 2018 Nov 30;9(94):36654-36665. doi: 10.18632/oncotarget.26336. eCollection 2018 Nov 30. Oncotarget. 2018. PMID: 30613349 Free PMC article.
75 results